Aisa Pharma to Present New Data from the Phase 2 RECONNOITER-1 Trial in Systemic Sclerosis-Associated Raynaud's Phenomenon at ACR Convergence 2026
AISA-021 significantly reduced median weekly Raynaud's attack frequency and duration while increasing the number of attack-free days in the Phase 2 RECONNOITER-1 clinical trial AISA-021 was well-tolerated, with a safety profile comparable to placebo Plasma concentration correlated...